基于血清药物化学、网络药理学的正骨丸治疗骨不连作用机制研究OA
Revealing the Mechanisms of Zhenggu Pills in Treating Bone Nonunion Based on Serum Pharmacochemistry and Network Pharmacology
目的:采用超高效液相色谱-四极杆-飞行时间串联质谱法(UPLC-Q-TOF-MS/MS)鉴定正骨丸的化学成分及入血成分,结合网络药理学预测其治疗骨不连的潜在作用机制,并通过小鼠骨折模型验证其疗效.方法:采用UPLC-Q-TOF-MS/MS检测正骨丸水提液、大鼠空白血浆及含药血浆,鉴定入血成分.利用SwissTargetPrediction、SEA和HERB数据库筛选正骨丸入血成分治疗骨不连的潜在靶点,通过STRING数据库构建蛋白质-蛋白质相互作用网络,并对核心靶点进行基因本体(GO)和京都基因与基因组百科全书(KEGG)通路富集分析.制备小鼠股骨骨折模型,于给药后第 7、14、21 天对小鼠股骨进行Micro-CT扫描及HE染色,评估骨折愈合情况.结果:从正骨丸中鉴定出 63 个化学成分,其中 30 个为入血成分.网络药理学筛选得到 33 个交集靶点、13 个核心成分(如阿魏酸、咖啡酸、金圣草素等)及 14 个核心靶点[如甘油醛-3-磷酸脱氢酶(GAPDH)、β1-连环蛋白(CTNNB1)、缺氧诱导因子 1α(HIF1A)等],主要涉及HIF-1、肿瘤坏死因子(TNF)、丝裂原活化蛋白激酶(MAPK)、核转录因子-κB(NF-κB)等信号通路.Micro-CT结果显示,与模型组相比,正骨丸组小鼠在给药第 7、14、21 天均表现出更明显的骨痂形成与骨重塑.给药第 14 天,正骨丸组小鼠的骨体积分数显著高于模型组(P<0.05);第 21 天,其骨体积分数显著低于模型组(P<0.05),骨折线消失,皮质骨连续性恢复,骨密度及骨小梁结构均显著改善.HE染色结果表明,正骨丸组小鼠骨折区域在第 7 天形成软骨组织,到第 14 天转变为编织骨,第 21 天编织骨逐渐转变为成熟的板层骨.结论:鉴定了正骨丸 30 个入血成分,揭示正骨丸中阿魏酸、芍药苷等成分可能作用于 GAPDH、CTNNB1 等核心靶点,通过调控HIF-1、MAPK、NF-κB等信号通路促进骨折愈合的机制,并经动物实验证实正骨丸促进骨痂形成、改善骨不连的疗效.
Objective:To identify the chemical components and blood-absorbed components of Zhenggu Pills by ultra-performance liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry(UPLC-Q-TOF-MS/MS),predict the potential treatment mechanism of Zhenggu Pills for bone nonunion by network pharmacology,and verify the efficacy of Zhenggu Pills by a mouse model of fracture.Methods:The water extract of Zhenggu Pills,rat blank plasma,and drug-containing plasma were detected by UPLC-Q-TOF-MS/MS to identify the blood-absorbed components.SwissTargetPrediction,SEA,and HERB databases were used to screen potential targets of the blood-absorbed components of Zhenggu Pills in the treatment of bone nonunion.A protein-protein interaction(PPI)network was constructed via the STRING database,followed by Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment analyses of the core targets.A mouse model of femoral fracture was established.Micro-CT scanning and hematoxylin-eosin(HE)staining were performed on days 7,14,and 21 after administration to evaluate the fracture healing.Results:A total of 63 chemical components were identified from Zhenggu Pills,among which 30 were identified as blood-absorbed components.Through network pharmacology screening,a total of 33 common targets were obtained,along with 13 core components(e.g.,ferulic acid,caffeic acid,and chrysoeriol)and 14 core targets[e.g.,glyceraldehyde-3-phosphate dehydrogenase(GAPDH),β1-catenin(CTNNB1),and hypoxia-inducible factor 1 alpha(HIF1A)].These were found to be mainly involved in the hypoxia-inducible factor 1(HIF-1),tumor necrosis factor(TNF),mitogen-activated protein kinase(MAPK),and nuclear factor-kappa B(NF-κB)signaling pathways.Micro-CT results showed that compared with the model group,the Zhenggu Pill group exhibited more pronounced callus formation and bone remodeling on days 7,14,and 21.On day 14,the bone volume fraction in the Zhenggu Pill group was higher than that in the model group(P<0.05).On day 21,although the bone volume fraction in the Zhenggu Pill group was lower than that in the model group(P<0.05),the fracture line disappeared,accompanied by the restored continuity of the cortical bone and markedly improved bone mineral density and trabecular bone structure.HE staining results indicated that in the Zhenggu Pill group,cartilage tissue formed in the fracture area on day 7,which transitioned into woven bone by day 14 and then gradually transformed into mature lamellar bone on day 21.Conclusion:This study identified 30 blood-absorbed components of Zhenggu Pills and revealed that components such as ferulic acid and paeoniflorin acted on core targets including GAPDH and CTNNB1 to promote fracture healing by regulating the HIF-1,TNF,MAPK and NF-κB signaling pathways.The therapeutic efficacy of Zhenggu Pills in promoting callus formation and ameliorating bone nonunion was further confirmed by animal experiments.
许翔月;雷霞;孙婷;刘雷;张宁;卞振华;赵德萍;刘晴;薛傲;华臻
南京中医药大学 附属无锡医院,江苏 无锡 214071南京中医药大学 附属无锡医院,江苏 无锡 214071黑龙江中医药大学 中医药研究院,黑龙江 哈尔滨 150040南京中医药大学 附属无锡医院,江苏 无锡 214071黑龙江中医药大学 中医药研究院,黑龙江 哈尔滨 150040南京中医药大学 附属无锡医院,江苏 无锡 214071黑龙江中医药大学 中医药研究院,黑龙江 哈尔滨 150040南京中医药大学 附属无锡医院,江苏 无锡 214071南京中医药大学 附属无锡医院,江苏 无锡 214071南京中医药大学 附属无锡医院,江苏 无锡 214071
医药卫生
正骨丸高效液相色谱-四极杆-飞行时间串联质谱法入血成分网络药理学骨不连
Zhenggu PillsUPLC-Q-TOF-MS/MSblood-absorbed componentnetwork pharmacologybone nonunion
《中国现代中药》 2026 (7)
1371-1385,中插13-中插14,17
国家自然科学基金青年科学基金项目(82205142)无锡市中医药管理局科技项目(ZYYB20)
评论